AngioDynamics Inc. (ANGO) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 43% of 52W Range • RSI-14 at 39.4 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ANGO currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.18) and Max Pain ($12.97) forces dealer call-delta covering toward $17.10.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
AngioDynamics Inc. (ANGO) advanced +1.81% to $12.35, trading at 43% of its 52-week range ($9.39 – $16.29). Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
LATHAM, N.Y., October 29, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatmen
LATHAM, N.Y., October 21, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatmen
Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic IRE takes effect
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANGO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANGO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, AngioDynamics Inc. (ANGO) ranks #344 by composite RQD confidence (50/100, grade D) and #441 by equity capitalization ($519.4M). Within this direct 5-issuer industry benchmark cohort, ANGO leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with ANGO at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANGO
ACTIVE
AngioDynamics Inc. | D | 50/100 | — | 54.6% | -23.4% | +1.81% | $519.4M | Benchmark Subject |
| RCEL Avita Medical Inc. | D | 44/100 | — | 82.1% | -35.0% | +1.27% | $516.8M | /rcel-vs-ango → |
| SENS Senseonics Holdings Inc. | D- | 38/100 | — | 44.7% | -35.0% | +4.39% | $515.5M | /sens-vs-ango → |
| SGHT Sight Sciences Inc. | D- | 38/100 | — | 86.2% | -35.0% | +3.57% | $527.2M | /sght-vs-ango → |
| DCTH Delcath Systems Inc. | D+ | 57/100 | — | 86.2% | 0.8% | -1.48% | $508.0M | /dcth-vs-ango → |
In its most recent audited fiscal period (FY2025, filed 2026-05-31), AngioDynamics Inc. (ANGO) reported GAAP revenue of $320.2M (+9.5% vs. FY2024 revenue of $292.5M , and +5.4% cumulative change since FY2023) , GAAP net income of -$36.7M, operating cash flow of $3.1M, and free cash flow of $508.0K (+103.5% YoY). On the balance sheet, ANGO closed FY2025 with $269.7M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-05-31 | $320.2M | -$36.7M | $3.1M | $508.0K | $269.7M | — |
| FY2024 (FY) | 2025-05-31 | $292.5M | -$34.0M | -$10.1M | -$14.6M | $291.6M | — |
| FY2023 (FY) | 2024-05-31 | $303.9M | -$184.3M | -$28.2M | -$28.2M | — | — |
As of 2026-11-01, AngioDynamics Inc. (NASDAQ: ANGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $12.35 (+1.81% 1D, market cap $519.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANGO ranks #344 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M) and SENS (Senseonics Holdings Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M). Among the 5-stock peer group, ANGO leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ANGO last traded at $12.35 (+1.81% on volume of 476,210 shares), positioning the stock -12.91% below its 50-day simple moving average ($14.18) and -1.04% below its 200-day simple moving average ($12.48). Across its 52-week range of $9.39 to $16.29, ANGO sits at the 42.9% percentile with a 14-day RSI of 39.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.81 to $13.89).
Why ANGO Stock advanced +1.81% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.